Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | AKT2 | P31751 | 1/20 | 0.35 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.35 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34475539 | 1.00 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL21573995 | 1.00 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL1829729 | 1.00 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL25231616 | 1.00 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL16877500 | 1.00 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL25229684 | 1.00 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL20104746 | 1.00 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL16878471 | 0.97 | CHEK1 (0.34) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL16878288 | 0.97 | CHEK1 (0.34) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL17797679 | 0.97 | CHEK1 (0.34) | CHEK1AURKARPS6KA5CHEK2MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 462 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070278-A | Bifunctional protein degradation agent containing aryl substituted heteroaryl and application thereof | 标新生物医药科技(上海)有限公司 | 2026-05-19 | — | — | CN | claimed |
| EP-4516787-A9 | FIVE-MEMBERED RING-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Hangzhou Polymed Biopharmaceuticals, Inc. (CN) | 2025-05-28 | — | — | EP | claimed |
| EP-4516787-A1 | FIVE-MEMBERED RING-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Hangzhou Polymed Biopharmaceuticals, Inc. (CN) | 2025-03-05 | — | — | EP | claimed |
| CN-119409684-A | Five-membered and six-membered compound, preparation method, pharmaceutical composition and application | 杭州多域生物技术有限公司 | 2025-02-11 | — | — | CN | claimed |
| US-20240423977-A1 | FIVE-MEMBERED RING-FUSED SIX-MEMBERED RING COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | HANGZHOU POLYMED BIOPHARMACEUTICALS, INC. (CN) | 2024-12-26 | — | — | US | claimed |
| US-20240294502-A1 | FIVE-MEMBERED-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | HANGZHOU POLYMED BIOPHARMACEUTICALS, INC. (CN) | 2024-09-05 | — | — | US | claimed |
| CN-115611856-B | Piperidine derivative and pharmaceutical composition, preparation method and application thereof | 宜昌人福药业有限责任公司 | 2024-07-05 | — | — | CN | claimed |
| WO-2024144149-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | 보로노이 주식회사 | 2024-07-04 | — | — | WO | claimed |
| CN-118076595-A | Five-membered and six-membered compound, preparation method, pharmaceutical composition and application | 杭州多域生物技术有限公司 | 2024-05-24 | — | — | CN | claimed |
| US-20240101552-A1 | CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2024-03-28 | — | — | US | claimed |
| EP-4298095-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITOR AND USES THEREOF | Sperogenix Therapeutics Limited (HK) | 2024-01-03 | — | — | EP | claimed |
| WO-2023241644-A1 | FIVE-MEMBERED RING-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 杭州多域生物技术有限公司 | 2023-12-21 | — | — | WO | claimed |
| EP-4215526-A1 | CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-07-26 | — | — | EP | claimed |
| WO-2023116920-A1 | PENTA- FUSED HEXA-HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | 杭州多域生物技术有限公司 | 2023-06-29 | — | — | WO | claimed |
| WO-2022162606-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITOR AND USES THEREOF | SPEROGENIX THERAPEUTICS LIMITED (CN) | 2022-08-04 | — | — | WO | claimed |
| US-20210300936-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | BEONE MEDICINES I GMBH (CH) | 2021-09-30 | — | — | US | claimed |
| US-20160159774-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2016-06-09 | — | — | US | claimed |
| WO-2016090079-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-06-09 | — | — | WO | claimed |
| US-8119805-B2 | Substituted disulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-21 | — | — | US | claimed |
| US-20100152158-A1 | Substituted Disulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-06-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240423977-A1 | FIVE-MEMBERED RING-FUSED SIX-MEMBERED RING COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | IRAK4, IRAK1, IRAK2 | CHEK1 3372/4885AURKA 736/4885RPS6KA5 545/4885 |
| US-20210300936-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | ADORA2A, ADORA3, ADORA2B | CHEK1 882/4885AURKA 834/4885RPS6KA5 815/4885 |
| US-20100152158-A1 | Substituted Disulfonamide Compounds | BDKRB1, BDKRB2, BRS3 | CHEK1 2036/4885AURKA 3501/4885RPS6KA5 601/4885 |
| US-20240101552-A1 | CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | LANCL2, CBS, LCP2 | CHEK1 4009/4885AURKA 4753/4885RPS6KA5 2447/4885 |
| US-20240294502-A1 | FIVE-MEMBERED-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | IRAK4, IRAK2, TRAF6 | CHEK1 2639/4885AURKA 317/4885RPS6KA5 200/4885 |
| US-20160159774-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | CHEK1 3061/4885AURKA 1849/4885RPS6KA5 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.